G20.B2 Insurance Policy Changes

ICD-10 G20.B2 is officially defined as "Parkinson's disease with dyskinesia, with fluctuations." code G20.B2 is referenced in 7 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G20.B2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Identified Oct 24, 2026High impact
Medical Policy Updates for Non-Migrated Members
Blue Cross Blue Shield of North Dakota's October 22, 2026 notice for non-migrated commercial and Medicaid Expansion members lists medical policies reviewed by its Internal Medical Policy Committee on Oct. 13, 2026. The revised policies include reformatted criteria and policies with coding changes, such as procedure codes and diagnosis codes added to or removed from policies, including physical therapy covered-diagnosis lists and Category III T codes. The notice also lists tabled policies (Tumor Markers, where further research is needed) and states that benefit determinations are made based on the medical policy in effect at the time of service.
Aetna · Identified Oct 23, 2026Medium impact
Actigraphy and Accelerometry (CPB 0710, reviewed 2026-10-15)
Aetna considers actigraphy testing (for example, Actiwatch) and accelerometry experimental, investigational, or unproven for listed uses, including diagnosing sleep disorders, diagnosing Alzheimer's disease, diagnosing hypertension, detecting seizures during sleep, and monitoring individuals with motor neuron diseases. CPT 95803 (actigraphy testing, minimum of 72 hours to 14 consecutive days of recording) and many listed ICD-10 codes, including those for depression, schizophrenia, Parkinson's disease and cerebral infarction, are not covered for the indications listed.
Aetna · Identified Aug 15, 2026Medium impact
Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)
Aetna considers CT perfusion studies of the brain medically necessary for evaluating acute stroke (less than 24 hours), including hemorrhagic stroke, subdural hemorrhage and transient ischemic attacks, for following up cerebral ischemia or infarction, for planning therapy for cervical or intracranial arterial occlusive disease, for identifying cerebral hyperperfusion after revascularization, and for evaluating the vascular status of solid tumors when MRI is degraded by susceptibility artifact. Aetna considers MRI perfusion studies medically necessary for diagnosing and following mass lesions such as glioma, for assessing acute stroke penumbra, and for assessing the hemodynamic significance of cervical or intracranial vascular stenosis and the efficacy of revascularization. Aetna considers CT perfusion experimental, investigational or unproven for indications including confirmation of brain death, differentiation of lung cancer from benign lesions, evaluation of head trauma and evaluation of cerebral vasospasm, and considers MRI perfusion unproven for indications including evaluation of traumatic brain injury, evaluation of persistent pain and prognostication of obstructive sleep apnea.
Aetna · Identified Aug 12, 2026Medium impact
Actigraphy and Accelerometry (CPB 0710, reviewed 2025-10-14)
Aetna considers actigraphy testing experimental, investigational, or unproven for indications including defining lithium response dimensions in bipolar disorders, detection or screening of apnea, diagnosis of Alzheimer's disease, diagnosis of hypertension, evaluation of depression, and evaluation of schizophrenia. Aetna considers accelerometry experimental, investigational, or unproven for indications including evaluating functional ability in the elderly, differential diagnosis of tremor syndromes, gait analysis in persons with hip osteoarthritis, and monitoring of physical activity during rehabilitation of persons with stroke. CPT code 95803 (actigraphy testing, recording, analysis, interpretation and report, minimum of 72 hours to 14 consecutive days of recording) and CPT codes 0533T through 0536T (continuous recording of movement disorder symptoms) are not covered for the indications listed in the policy.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Deep Brain Stimulation
Unilateral or bilateral deep brain stimulation of the thalamus may be considered medically necessary for disabling, medically unresponsive tremor due to essential tremor or Parkinson disease, and bilateral thalamic stimulation for tremor in both upper limbs. Unilateral or bilateral stimulation of the globus pallidus or subthalamic nucleus may be considered medically necessary for Parkinson disease and for chronic, intractable primary dystonia in individuals older than 7 years. Adaptive deep brain stimulation for Parkinson disease, deep brain stimulation for other movement disorders, cluster headaches, and the other psychiatric or neurologic disorders listed in the policy are considered investigational. A 06/05/2025 update added that adaptive deep brain stimulation for Parkinson disease is considered investigational, and a 09/16/2026 update changed the description of deep brain stimulation systems and removed ICD-9 procedure and diagnosis codes from the code reference, with the policy statements unchanged.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Apomorphine
BCBSMS requires prior authorization for apomorphine. Apokyn (apomorphine) is covered for acute, intermittent treatment of 'off' episodes in patients with advanced Parkinson's disease, while Onapgo (apomorphine) for motor fluctuations in adults with advanced Parkinson's disease is considered not medically necessary when other options covered by the Plan are available. The 09/01/2025 revision changed the policy title to Apomorphine, added the Onapgo not medically necessary statement, and added that services not approved through the BCBSMS PA review process are not medically necessary; the 12/02/2025 Pharmacy & Therapeutics review updated sources.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography
Dopamine transporter imaging with SPECT using ioflupane may be considered medically necessary when used for individuals with clinically uncertain Parkinson disease or clinically uncertain dementia with Lewy bodies. Use of this imaging is investigational for all other indications. The use of DaT-SPECT for the diagnosis, management, or surveillance of Alzheimer disease is considered out of scope for this policy.

Watch G20.B2

Get one email when a payer policy names G20.B2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G20.B2?

There are 7 tracked policy changes affecting code G20.B2, including updates from Blue Cross Blue Shield of North Dakota, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G20.B2?

Payers that have issued tracked updates for code G20.B2 include: Blue Cross Blue Shield of North Dakota, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code G20.B2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G20.B2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G20.B2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Medical Policy Updates for Non-Migrated Members

Actigraphy and Accelerometry (CPB 0710, reviewed 2026-10-15)

Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)

Actigraphy and Accelerometry (CPB 0710, reviewed 2025-10-14)

Deep Brain Stimulation

Apomorphine

Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography

What insurance policy changes affect code G20.B2?

Which payers have updated policy for code G20.B2?

How do I get notified when code G20.B2 policy changes?

Why do payers change policies for code G20.B2?